Fundamentals data is not available for this company.
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-25 | 334.95 | 7.96 | (33.49)¢ | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-26 | 390.46 | 54.40 | 41.44¢ | 25.1 | n/a | n/a | n/a | 0.0% |
31-Dec-27 | 450.61 | 80.45 | 60.09¢ | 17.3 | 0.4 | +45% | n/a | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
No recent information was found.
Dynavax, Merck team up on hepatitis B vaccine | 02-Nov-2007 | BayArea.com |
Merck Buys License to Sell New Vaccine for Hepat... | 01-Nov-2007 | New York Times |
Business Digest | 20-Jan-2006 | BayArea.com |
Currency | US Dollars |
Share Price | $ 11.02 |
Change Today | $ 0.60 |
% Change | 5.71 % |
52 Week High | $14.40 |
52 Week Low | $9.51 |
Volume | 3,460,170 |
Shares Issued | 65.06m |
Market Cap | $716.68m |
RiskGrade | 699 |
Strong Buy | 1 |
Buy | 3 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 0 |
Total | 5 |
Time | Volume / Share Price |
14:27 | 100 @ $11.02 |
14:26 | 100 @ $11.02 |
14:26 | 100 @ $11.02 |
14:26 | 100 @ $11.02 |
14:26 | 100 @ $11.02 |
You are here: research